Investor Presentaiton

6 Investor presentation Full year 2022 Diabetes value market leadership increased by 1.8%-points to 31.9% Novo Nordisk global diabetes value market shares Diabetes value market leadership expansion driven by the GLP-1 franchise 60% -Diabetes -GLP-1 -Insulin 54.9% 52.7% 50.5% 50% 47.5% Novo NordiskⓇ Diabetes care sales grew by 14% with global value market share increase driven by GLP-1 market share gains in both IO and NAO GLP-1 value market share has increased by 2.2%-points in the last 12 months, driven by: • OzempicⓇ launches and uptake in 75 countries 44.5% 44.3% 44.6% . 43.8% 40% RybelsusⓇ uptake in North America Operations and launches in International Operations • Global GLP-1 volume growth of ~50% 31.9% 28.6% 30.1% 29.3% 30% 0% T 2019 2020 2021 2022 CER: Constant exchange rates; IO: International Operations; NAO: North America Operations Source: IQVIA MAT, Nov 2022 (Spot rate) Note: Sales growth rates are at CER GLP-1 is only -5% of total diabetes prescriptions

View entire presentation